Bauke de Boer

Bauke de Boer is a researcher at the University Medical Center Groningen, part of the University of Groningen, specializing in acute myeloid leukemia research. Their work contributes significantly to UN Sustainable Development Goals related to health and wellbeing, with a research fingerprint showing deep expertise in Myeloid Immunology (100%), Acute Myeloid Leukemia (68%), and Xenograft studies (68%).

Dr. de Boer completed their PhD in 2020 with a thesis titled "Unraveling clonal heterogeneity in acute myeloid leukemia," demonstrating early expertise in AML complexity. Their research focuses on molecular mechanisms driving leukemia progression, particularly inflammatory signaling pathways and metabolic regulation in cancer cells.

Analysis of their publication trends reveals a consistent focus on AML biology with three major research threads: 1) The IL1-IL1RAP inflammatory axis in the leukemic microenvironment, 2) Metabolic regulation through PDK1 in genetically distinct AML subtypes, and 3) Clonal heterogeneity and evolution in leukemia. These studies collectively aim to identify novel therapeutic targets for more effective AML treatments.

Dr. de Boer maintains a robust collaborative network, frequently working with prominent researchers including E. Vellenga, J.J. Schuringa, G. Huls, and A.B. Mulder. Their publications in high-impact journals like Nature Communications and Haematologica demonstrate significant contributions to the field, with several papers receiving notable citations and media attention.

As part of the University Medical Center Groningen's hematology research team, Dr. de Boer contributes to a comprehensive research program investigating leukemia biology from multiple angles, integrating molecular, cellular, and translational approaches to advance understanding and treatment of this aggressive blood cancer.